key: cord-1007533-yb5rdt59
authors: Dejnirattisai, Wanwisa; Zhou, Daming; Ginn, Helen M.; Duyvesteyn, Helen M.E.; Supasa, Piyada; Case, James Brett; Zhao, Yuguang; Walter, Thomas S.; Mentzer, Alexander J.; Liu, Chang; Wang, Beibei; Paesen, Guido C.; Slon-Campos, Jose; López-Camacho, César; Kafai, Natasha M.; Bailey, Adam L.; Chen, Rita E.; Ying, Baoling; Thompson, Craig; Bolton, Jai; Fyfe, Alex; Gupta, Sunetra; Tan, Tiong Kit; Gilbert-Jaramillo, Javier; James, William; Knight, Michael; Carroll, Miles W.; Skelly, Donal; Dold, Christina; Peng, Yanchun; Levin, Robert; Dong, Tao; Pollard, Andrew J.; Knight, Julian C.; Klenerman, Paul; Temperton, Nigel; Hall, David R.; Williams, Mark A.; Paterson, Neil G.; Bertram, Felicity K.R.; Seibert, C. Alistair; Clare, Daniel K.; Howe, Andrew; Raedecke, Julika; Song, Yun; Townsend, Alain R.; Huang, Kuan-Ying A.; Fry, Elizabeth E.; Mongkolsapaya, Juthathip; Diamond, Michael S.; Ren, Jingshan; Stuart, David I.; Screaton, Gavin R.
title: The antigenic anatomy of SARS-CoV-2 receptor binding domain
date: 2021-02-18
journal: Cell
DOI: 10.1016/j.cell.2021.02.032
sha: bd95659de97b62c25b9cff6ab87b60e07e2135b6
doc_id: 1007533
cord_uid: yb5rdt59

Antibodies are crucial to immune protection against SARS-CoV-2, with some in emergency use as therapeutics. Here we identify 377 human monoclonal antibodies (mAbs) recognizing the virus spike, and focus mainly on 80 that bind the receptor binding domain (RBD). We devise a competition data driven method to map RBD binding sites. We find that although antibody binding sites are widely dispersed, neutralizing antibody binding is focused, with nearly all highly inhibitory mAbs (IC50<0.1μg/ml) blocking receptor interaction, except for one that binds a unique epitope in the N-terminal domain. Many of these neutralizing mAbs use public V-genes and are close to germline. We dissect the structural basis of recognition for this large panel of antibodies through X-ray crystallography and cryo-electron microscopy of 19 Fab-antigen structures. We find novel binding modes for some potently inhibitory antibodies and demonstrate that strongly neutralizing mAbs protect, prophylactically or therapeutically, in animal models.

A severe viral acute respiratory syndrome named COVID-19 was first reported in Wuhan, China in December 2019. The virus rapidly disseminated globally leading to the pandemic we are suffering, with over 100M confirmed infections and over 2.2M deaths (https://www.worldometers.info/coronavirus/). The causative agent, SARS-CoV-2, is a beta coronavirus, related to SARS-CoV-1 and MERS coronaviruses, which both cause severe respiratory syndromes.

The sequence of SARS-CoV-2 was released in early January 2020 and this led to the mobilisation of an unprecedented international scientific response (Chen et al., 2020a) . Over two hundred vaccine candidates are in development (Krammer, 2020) Coronaviruses have 4 structural proteins, nucleocapsid, envelope, membrane and spike (S). S from both SARS-CoV-2 and SARS-CoV-1 uses angiotensin-converting enzyme 2 (ACE2) as the cell surface receptor , ACE2 is expressed in a number of tissues, including epithelial cells of the upper and lower respiratory tracts. S consists of two subunits, S1 which mediates receptor binding and S2 responsible for viral and host cell membrane fusion Wrapp et al., 2020) . It is a dynamic structure capable of transitioning to a post-fusion state (Cai et al., 2020) by cleavage between S1 and S2

following receptor binding or trypsin treatment. In most SARS-CoV-2 sequences a furin protease cleavage site is inserted between the S1 and S2 subunits and mutation of the J o u r n a l P r e -p r o o f cleavage site attenuates disease in animal models (Johnson et al., 2020) . The S1 fragment, at the membrane distal tip of S, includes an N-terminal domain (NTD) and receptor binding domain (RBD). While both regions are immunogenic, the RBD contains the interacting surface for ACE2 binding (Lan et al., 2020) . Although usually packed down against the top of S2, RBDs can swing upwards to engage ACE2 (Roy et al., 2020) . Monoclonal antibodies (mAbs) recognize one or both of 'up' and 'down' conformations . The S protein is relatively conserved between SARS-CoV-2 and SARS-CoV-1 (76%), but the RBD and NTD are less conserved (74% and 50% respectively) than the S2 domain (90%) (Jaimes et al., 2020) . Conservation with MERS-CoV and the seasonal human coronaviruses is much lower (19-21%). Overall SARS-CoV-2 antibodies show limited crossreactivity even with SARS-CoV-1 (Tian et al., 2020) .

Previous studies of SARS-CoV-2 have indicated that most potent mAbs bind close to the ACE2 interacting surface on the RBD to block the interaction with ACE2 (Zost et al., 2020; ) expressed on target cells or disrupt the pre-fusion conformation (Huo et al., 2020; Yuan et al., 2020a; . There has been intense interest in S for the development of protective SARS-CoV-2 vaccines or for therapeutic mAbs, several of which are in clinical evaluation and even being deployed under EUA (DeFrancesco, 2020).

Here we characterize a panel of 377 human mAbs from recovered COVID-19 patients. We devise a generally applicable method combining biophysical competition measurements with a smaller number of crystallographic structure determinations, to pin-point the attachment site for all 80 mAbs that bind the RBD. The resulting map shows that the antibody footprints cover the majority of the RBD surface, grouping into five epitopes by cluster analysis. In addition, we have determined 19 structures, mainly of Fab fragments with either spike or J o u r n a l P r e -p r o o f RBD, by X-ray crystallography or cryo-electron microscopy (cryo-EM). These include many of the most potently inhibitory antibodies, all RBD-binders except for a single N-terminal domain binder. We analyse the modes of binding for antibodies with several public heavy chain (HC) V-regions. Of these some engage identical sites through conserved HC CDR1 and CDR2 (H1, H2) interactions, whilst others use variable length HC CDR3s (H3) to bind at different points. We find that shuffling the light chain pairing within one of these families leads to tighter binding. Other potently neutralizing antibodies have novel interaction sites and several of these bear somatic mutations that create N-linked glycosylation sites in H1-H3 . By studying the valency of antibody binding to virus particles we show that some of the most potent antibodies can neutralise at low receptor occupancies. The most potent mAbs neutralize the virus in the low picomolar range and show both prophylactic and therapeutic activity in a stringent murine model of SARS-CoV-2 pathogenesis.

We studied a cohort of 42 patients who had proven SARS-CoV-2 infection diagnosed by qRT-PCR (Table S1 ). Patients were recruited using the ISARIC protocol following informed consent and recalled following convalescence (31-62 days). ELISAs were performed against full-length stabilized S protein (Wuhan-Hu-1 strain, MN908947) where residues 986 and 987

in the linker between two helices in S2 were mutated to a Pro-Pro sequence to prevent the conversion to the post-fusion helical conformation Wrapp et al., 2020) , or N protein ( Figure S1A ). As has been described previously, antibody titres varied between patients, and there was a strong correlation between neutralization titre or the level of anti-S expressing memory B cells with disease severity (Chen et al., 2020b) (Figure S1B-C).

To generate mAbs, two strategies were used. First, IgG expressing B cells were sorted, 4 cells per well, cultured with IL-2, IL-21 and 3T3-msCD40L cells for 13-14 days, and supernatants were tested for reactivity to S protein; positive clones were identified by RT-PCR ( Figure   S2A ). In a second method, B cells were stained with labelled S or RBD proteins, and single positive cells were sorted and subjected to RT-PCR ( Figure S2B ). Cell recovery was higher in the severe COVID-19 cases (Figure S1C) , and in total we isolated mAbs from 16 patients (9 mild, 7 severe).

377 antibodies were produced, which reacted to full length S by ELISA. MAbs were further screened for reactivity to S1 (34%), S2 (53%), RBD (21%) and the NTD (11%), with the remaining 13% reactive only to full-length trimeric spike ( Figure S3A ). Analysis of antibody sequences revealed low levels of somatic mutation of germline sequences for both heavy (mean 4.11 ± 2.75 amino acids) and light chains (mean 4.10 ± 2.84 amino acids) ( Figure   S3B ). In general, responses within and between individuals were highly polyclonal with diverse V-gene usage ( Figure S3C ). We tested cross-reactivity of the 377 anti-S antibodies generated from SARS-CoV-2 patients to full-length S proteins from all human alpha and beta-coronaviruses ( Figure 1A ). Cross-reactivity was observed with SARS-CoV-1 (52%), MERS (7%), OC43 (6%), HKU1 (7%), 229E (1%), and NL63 (1%). However, for antibodies recognising RBD, cross-reactivity was restricted to SARS-CoV-1, the RBD of which shares 74% sequence identity with SARS-CoV-2, much more than the other human CoVs (19-21%).

Antibodies cross-reacting between the RBDs of SARS-CoV-2 and SARS-CoV-1 showed similarly low levels of germline mutation to the whole pool of S reactive antibodies.

However, for antibodies cross-reacting between SARS-CoV-2 and the four seasonal coronaviruses there were more germline mutations particularly in the heavy chain ( Figure   J o u r n a l P r e -p r o o f S3D). One plausible explanation for the increase in germline mutation in the cross-reactive clones is that they were selected from the memory pool of seasonal coronavirus-specific B cells, rather than generated de novo after SARS-CoV-2 infection.

Next, we investigated the neutralizing activity of all 377 mAbs using a focus reduction neutralization test (FRNT) using Vero cells. Only 5% of non-RBD mAbs showed neutralizing activity (IC 50 < 10 µg/ml), whereas 60% of RBD-specific mAbs showed neutralizing activity ( Figure 1B ) consistent with previous studies of SARS-CoV-1 and SARS-CoV-2 ( Barnes et al., 2020) .

In total, 19 of 80 anti-RBD antibodies yielded IC 50 levels of < 0.1 µg/ml (Figure 1C) , which we define as potent neutralizers. FRNT50 values for a selection of antibodies is shown in Table S2 . A number of antibodies outside the RBD had weak neutralizing activity (IC 50 values of 0.29-7.38 µg/ml). MAb 159, which binds to the NTD (see below), was one of the most potent inhibitory antibodies we obtained with an IC 50 of 5 ng/ml.

We measured the ability of anti-RBD mAbs to block interaction with ACE2 using a competitive ELISA. For antibodies showing neutralization, there was broad correlation between inhibitory potency and ACE2 blocking while NTD-binding mAb 159 did not block ACE2 binding ( Figure 1C) .

To investigate the contribution of RBD binding antibodies to neutralization in polyclonal serum, we immunodepleted sera from 8 convalescent donors with recombinant RBD; depletion of anti-RBD activity was confirmed by ELISA. Neutralization assays were J o u r n a l P r e -p r o o f performed in RBD-depleted and mock-depleted samples and showed the major contribution made by anti-RBD antibodies with 55-87% (mean 61.5%) of neutralisation due to RBDbinders. Whilst some RBD epitopes (eg quaternary epitopes) may be resilient to RBD depletion this indicates that although the large majority of non-RBD antibodies do not neutralise, those that do have a substantive role in the polyclonal neutralizing response to SARS CoV-2 ( Figure 1D ).

To acquire greater insight as to the mAb binding sites on the RBD, we measured pairwise competition between antibodies using biolayer interferometry (BLI) in a 96-well plate format. For 80 antibodies, 4404 of the 6340 non-diagonal elements of the square competition matrix were populated. The antibodies were classified into mutually competing groups using cluster analysis (Methods). We derived the topography of binding for all the tested antibodies directly from the competition data with the aid of existing structural data. We expanded the competition matrix to include 3 additional ('external') antibodies of known binding positions (Methods). The external antibodies and one structure determined in the present study were set to their known positions on a smoothened mesh derived from the solvent-accessible surface of the RBD. The remaining 79 antibodies were assigned randomly to a starting vertex on the mesh and their positions refined by iterative minimization of a simple target function to match observed competition (antibodies were modelled as competing spheres of 22 Å diameter, see Methods). Minimization was performed 1000 times using Monte Carlo sampling from random starting positions. The results with lowest residuals were filtered using cluster4x (Ginn, 2020) . The final positions of the mAbs (Table S3) were taken as the sampled position with the lowest average square distance to all other sampled positions. This consensus prediction replicates well the observed competition data (correlation coefficient J o u r n a l P r e -p r o o f 0.84). To assess the accuracy of the method, six antibodies whose positions we have since determined (see below), were compared with their predicted locations. The average error was 7.6 Å.

To facilitate interpretation of the results, we introduce a naming convention for the RBD by comparison with a human torso (Figure 2A) . The predicted locations, covering most of the RBD surface, were classified into 5 groups using a clustering algorithm (Methods and cluster4x (Ginn, 2020)) ( Figure 2B,C) . The left flank cluster is distinct from the other 4 clusters which show marked competition at their boundaries and interact sequentially from the left shoulder, neck, right shoulder to right flank. Competition was strongest between the left shoulder and neck, although the neck and right shoulder groups also cross-compete strongly ( Figure 2C ).

The ACE2 binding site is shown in Figure 2D , and the positions of the 80 individual antibodies (plus externals) are depicted in Figure 2E . The neck cluster is the site of attachment of a number of antibodies possessing the public IGVH3-53 V-region (Yuan et al., 2020b) and strongly overlaps the ACE2 binding site (Figure 2D -E). The left flank cluster includes previously determined structures EY6A, CR3022 and H014, all of which are reported to show neutralizing activity, but do not compete with ACE2 binding (Yuan et al., 2020a; Huo et al., 2020; Lv et al., 2020; Wrobel et al., 2020) . Although the left flank is largely separated from the neck and shoulders, two mAbs (38, 178) nevertheless compete and are situated closer to antibodies of the left shoulder, compared to more isolated antibodies (1, 22, 177) ( Figure 2E ). Some regions of the RBD are notable for the lack of antibody binding. The right and left flank clusters both interact with the neck and shoulder clusters, but this does not produce a complete 'belt' of antibodies around the waist of the J o u r n a l P r e -p r o o f RBD. Antibodies are not seen against the N and C-termini, either because of incomplete presentation on the RBD or occlusion by other parts of the spike.

In Figure 2F we map neutralisation to antibody position on the RBD. As expected, there is good correlation between overlap with the ACE2 footprint and neutralisation. However, there were examples of non-neutralizing antibodies that were good ACE2 blockers, and it is not clear why these antibodies performed poorly. From the competition data, we can identify pairs of non-competing potently neutralizing mAbs and, if we relax the potency threshold, triplets (Table S3) . Such combinations might prove useful in therapeutic cocktails (Baum et al., 2020; Dong et al., 2021) .

There are undoubtedly mechanisms of neutralization beyond ACE2 blocking, for instance 159 binds the NTD, remote from the ACE2 binding site (see below). Interestingly, antibodies co-locating with known neutralizing/protecting antibodies EY6A/H014 and S309 (Huo et al., 2020; Lv et al., 2020) in the left and right flank clusters respectively did not show appreciable neutralization in our assays. We speculate that our assay might not be equally sensitive to all mechanisms of neutralisation.

We determined the kinetics of RBD attachment for 20 potent RBD binders (Table S2) . K D values for Fab fragments ranged from 0.7 to 7.6 nM and off-rates, potentially associated with therapeutic efficacy, were in the order of 1,000-10,000 s (Ylera et al., 2013) . We also characterised expression levels, thermostability, monodispersity, and freeze-thaw robustness for 34 mAbs (Table S4 ). All were stable at elevated temperatures with a first observed Tm at J o u r n a l P r e -p r o o f 65-80 °C (Walter et al., 2012) with more than 99% of the mass in a single species. A few appeared to have more complex unfolding pathways. Nearly all were resilient to 20 freezethaw cycles.

Based primarily upon the neutralization data ( (Figures 3, S4, S5 ).

By selecting antibodies that are the most potent in the FRNT assay, we omitted a large number of high affinity antibodies. This can be seen for instance in mAb 45, which had a K D of 0.018 µg /ml. This mAb showed weak neutralisation (IC 50 2 µg /ml) and was predicted as mapping to the right flank ( Figure 4C ). Structure determination of 45 in a ternary complex with potent neutraliser 88 and RBD, revealed binding in the predicted position, a site not reported previously, adjacent to S309, an antibody with 79 ng ml −1 IC 50 Piccoli et al., 2020) (Figures 3, 4C, 4D) , demonstrating the value of the predictive mapping in identifying novel epitopes.

J o u r n a l P r e -p r o o f Antibody 384 is our most potently neutralizing mAb with an IC 50 of 2 ng/ml. Its binding mode is unlike any other SARS-CoV-2 antibody reported to date. It approaches the binding site on the top of the neck and left shoulder from the front with a relatively small footprint of 630 Å 2 (460 Å 2 contributed by the heavy chain and 170 Å 2 by the light chain). Although the orientation of 384 is similar to a group of previously reported Fabs (CV07-270, p2b-2f6 and bd629, (Kreye et al., 2020; Ju et al., 2020; Du et al., 2020) ), it is shifted 20 Å towards the left shoulder such that it does not contact the right chest (Figures 3, 4E) . Only CDRs H2 and H3

of the Fab 384 HC interact with the antigen (Figure 5A ). It is unusual in that the 18-residue long H3 of Fab 384 binds across the top of the neck to reach the H3 binding site of the important IGVH3-53 group of Fabs (discussed below), making hydrophobic interactions from F104 and L105 at the tip to L455 and F456 of the RBD ( Figure 5A ). However, the main interactions that contribute to the binding affinity and orientation are with RBD residues 482-486 on top of the shoulder. W107 of H3 makes strong π-interactions with G485, Y59 of H2 contacts V483 and makes bifurcated H-bonds to the carbonyl oxygen of G482 and amino nitrogen of E484 which in turn salt-bridges with R52 and H-bonds to the side-chains of T57 and Y59 ( Figure 5A ). E484-F486 also form a two-stranded antiparallel β-sheet with residues A92-A94 of L3 and make stacking interactions from F486 to Y32 of L1.

The potent neutralisers we have identified frequently use public HC V-regions (shared by most people, compared to private, patient specific responses). Thus 5 potent mAbs use IGVH3-53 (bearing 3-10 non-silent mutations) ( Figure 5B ). IGVH3 antibodies have been observed before (e.g., B38, CB6 and CC12.3 (Wu et al., 2020b; Shi et al., 2020; Yuan et al., 2020b; Hurlburt et al., 2020; Du et al., 2020; Clark et al., 2020) ). Our competition data showed that these all bind at a similar site. We determined structures for J o u r n a l P r e -p r o o f three members of the group, 150, 158 and 269 (the others are 175 and 222) and found that they bind almost identically at the back of the neck with similar footprints of about 800 Å 2 (Figures 3, S4B) . The flat binding site of the RBD and the approach angle of the Fabs limit their H3 length (11 residues) and the number of contacts H3 makes with the RBD ( Figure   5C ), which is compensated for by the interactions from H1, H2 and all CDRs of the light chain. Thus for 158, H3 makes four direct contacts (≤ 4 Å) and two hydrogen bonds to the RBD, whilst H1 and H2 together make 11 contacts and 6 hydrogen bonds, and the three LC CDRs contribute 6 contacts and 5 hydrogen bonds ( Figure 5C ). We note strong LC interactions with residue N501 of the RBD, which is mutated in recent variants (B.1.1.7, B.1.351, P.1). The H3 length matches that reported as optimal for this V-region (Yuan et al., 2020b) , and the H3 sequence of mAb 150 is strongly similar to that of CC1.12 (Yuan et al., 2020b) ( Figure S4A ). Thus H1 and H2 determine the mode of engagement, as seen in previous studies of antibodies with this V-region ( Figure S4C ) (Yuan et al., 2020b) .

A second V-region which repeatedly confers potent (IC 50 < 0.1µg/ml) neutralisation is 165, 253 and 318) . These have even fewer non-silent mutations (2 to 5) and longer HC CDR3s (12-16 residues). Three antibodies (55, 165, 253) harbour a disulfide bond in their CDR3s, compete strongly with each other for binding and map to the neck epitope, but do not compete with mAb 318. In mAb 253 the disulfide brackets a glycosylation sequon (see below). The crystal structure of a complex including Fab 253 confirmed that it binds within the dominant neck epitope (Figure 3) . In contrast competition mapping indicates that Fab 318 binds at the right shoulder epitope ( Figure 2E ). It appears that for this V-region the CDR3 is more critical to recognition and can switch binding to different epitopes on the same antigen, but nevertheless can bind strongly with near germline V-region sequences.

The final V-region with at least 2 potent neutralizers is IGHV3-66, which was found a total of 5 times with 2 potent neutralizers (282 and 40). These two (with rather few mutations from germline and CDR3 lengths 12 and 13 respectively) compete strongly. Once again, we determined a complex structure for one (Fab 40) and demonstrated that, as expected from the competition data, this antibody binds squarely in the dominant neck epitope, almost indistinguishable from those using IGHV3-53 ( Figure 5D ). One IGHV3-66 mAb (398) has a much longer H3, 21 residues, and is predicted to bind on the edge of the neck epitope ( Figure   2E ).

IGHV3.11 is found in the most potent neutraliser, 384 but is also used by CV07-270 (Kreye et al., 2020) . CV07-270 is swung forward and sideways (compared to 384, Figure 4E ) so that it does not compete with ACE2 binding, suggesting that the potency of 384 derives from the extended H3 interaction which reaches across the ACE2 binding site.

Whilst IGHV3-30 is found in 11 RBD binders, none are potent neutralisers. H3 lengths for IGHV3-30 RBD binders vary from 12 to 20 residues, suggesting they bind at different sites, as confirmed by the structures of two representatives, 75 (in a ternary complex with 253) and 45 (in a ternary complex with 88) ( Table S5) . 75 binds on the right shoulder and overlaps the ACE2 binding site (Figure 3) , however the only HC-RBD contact is via the extended 20 residue H3, whereas the bulk of the interaction is with the LC, outside of the ACE2 footprint, and ACE2 binding could likely displace the extended H3 loop ( Figure 5E ). 45, with an H3 length of 14 residues, binds differently, well away from the ACE2 binding site on the left flank and so would not be expected to neutralise (Figure 3) . Thus for IGHV3-30 antibodies, J o u r n a l P r e -p r o o f the mode of binding is modulated by H3 and not focused on a region overlapping the ACE2 site.

In summary, the major public V-regions used by potent antibodies generally target the neck epitope, usually with a common mode of binding dictated by the V-region (although they can occasionally switch epitopes), but this is not true for weaker neutralisers. This likely explains the overwhelming representation of a common mode of binding at the neck epitope in the structures determined to date ( Figure S4C ).

For the three potent anti-RBD antibody clusters where >2 members shared the same IGVH impact on antigen binding, this finding is relatively poorly studied at the molecular level (Wright et al., 1991; van de Bovenkamp and Hafkenscheid, 2016 However, mutations that eliminate glycosylation had a deleterious effect on neutralisation for these two and for the 253H165L chimera ( Figure S6 ). Structures were therefore determined for mAbs 88, 316 and 253 in complex with RBD and with spike (Figures 3, 6D , S6, Tables   S5, S6) .

Antibodies 88 and 316 contain glycosylation sites in H1 (N35) and H2 (N59) respectively.

The crystal structure of the RBD-316 Fab complex at 2.3 Å resolution shows well-defined density for 3 glycans including an α1,6 linked fucose ( Figure 6D and S6E). The structure of Fab 88 was determined in a ternary complex with 45 and RBD to 2.53 Å resolution (the ChCl domains of 88 were disordered but the VhVl domains had well defined density). Antibody 88 binds to the back of the neck whereas 316 binds to the top of the neck, orientated radically differently, however the H3s of the two Fabs overlap well ( Figure 6D and S6). Figure 6D ).

In all cases the sugar is presented close to the top of the left shoulder, and in 2 out of 3 cases interacts directly but rather weakly with the antigen. The high frequency of sequon generation despite the rather few somatic mutations is intriguing and suggests positive selection.

On isolated stabilised spikes the RBD is found in two orientations; 'up' and 'down' (Yuan et al., 2017; Roy et al., 2020) . Both of these form an ensemble of conformations, up conformations vary by up to 20° and down can include a tighter packed 'locked' conformation Toelzer et al., 2020; Carrique et al., 2020; Xiong et al., 2020) . Table S6 and Figure 7A ).

Although Fab 384, despite its high potency, predominantly binds only one RBD per trimer, analysis of different particle classes revealed some weak density decorating the other RBDs, also in the down position, while a subtle movement can be seen between the RBDs of different classes ( Figure S5L ). This could be attributed to a more favourable RBD conformation that can only be sustained by one RBD at a time.

To visualise the binding of the highly potent mAb 159, it was necessary to incubate spike with 159 IgG (the Fab alone showed no binding). This revealed all three NTDs of the spike decorated by 159 with RBDs in either one-up or all-down configurations ( Figure S5M ). The 159 binding site is ~15 Å from that of a previously reported NTD binder, 4A8 (Chi et al., 2020) , in which the CDR-H3 binds on the side of the NTD between the 144-153 and 246-258 loops ( Figure 7B ). The CDR-H3 of 159 is 11 residues shorter than that of 4A8 (Chi et al., 2020) and binds on the top centre of the NTD interacting with residues 144-147, 155-158, 250-253 and the N-terminus of NTD. All 3 CDRs of the heavy chain contribute to a footprint of 515 Å 2 on the NTD, whereas the light chain has little contact with the NTD (35 Å 2 ), similar to 4A8 (Chi et al., 2020) ( Figure 7B , C).

We measured binding of full-length mAbs and Fab fragments to intact SARS-CoV-2 by ELISA and compared these with neutralization curves for antibodies for which we have structural information ( Figure 7D and Table S7 ). For the anti-NTD mAb-159 binding of full-length and Fab to virions were nearly identical, in-line with NTDs on a trimer being too far apart to allow bivalent engagement (118 Å) ( Figure 7C ) and suggesting that mAb-159 cannot span adjacent spike trimers at the virion surface. Interestingly, whilst IgG-159 is a potent neutraliser, Fab-159 has no neutralizing activity, suggesting that the Fc portion is crucial for activity, although the mechanism is not immediately apparent and does not involve blocking ACE2 interaction.

Loss in binding and neutralisation with Fabs compared to IgG is quite modest for mAb-88, which attaches in the all-up conformation ( Figure 7D and S6), but much more marked for mAbs that bind the all-down form of the spike (253, 316, 384). Thus mAb-384 showed 79fold less virus binding and a 486-fold loss of neutralisation activity when reduced to Fab, suggesting that both Fab arms are used when antibody interacts with virions and also highlights the exceptional K D of Fab-159, 2.5 to 81-fold better than the other Fabs depicted in Figure 7D and Table S7 . Finally, we have used the following formula to estimate the relationship between antibody binding and neutralization: Percent occupancy = BMax*

Ab required to reach 50% FRNT and Kd is the concentration of Ab required to reach halfmaximal binding. mAb-384 can achieve NT50 with an estimated average occupancy of 12% of the maximum available antibody binding sites on each virion, perhaps in part due to the avidity conferred by bivalent attachment (Table S7) . Bivalent attachment to the down conformation may also lock all three RBDs, preventing attachment to ACE2. Some of the variation in the effects seen in Figure 7D and Table S7 probably arises from the interplay J o u r n a l P r e -p r o o f between the angle and position of attack of the antibody arm to the RBD and the constraints on flexibility in the system.

We determined the efficacy of our most promising neutralizing human mAbs in vivo. We prevented SARS-CoV-2-induced weight loss ( Figure S7A ). In the lung homogenates of antibody 40 and 88 treated animals, no infectious virus was detected at 7 dpi, whereas substantial amounts were present in animals treated with the isotype control mAb ( Figure   S7B ). Consistent with these results, viral RNA levels were reduced by approximately 10,000-100,000-fold compared to isotype control mAb-treated animals ( Figure S7C ). In peripheral organs, including the heart, spleen, or brain viral RNA levels were reduced or undetectable in mAb 40 or 88 treated animals ( Figure S7D -G). Moreover, levels of viral RNA at 7 dpi were markedly lower in the nasal washes of animals treated with mAbs 40 and 88 compared to the isotype control.

To further evaluate the in vivo potency of our mAbs, we assessed the therapeutic activity of a larger panel at 1 dpi (D+1) with 10 3 PFU of SARS-CoV-2. Although varying degrees of J o u r n a l P r e -p r o o f protection were observed for individual mAbs, weight loss was significantly reduced in all animals treated with anti-SARS-CoV-2 mAbs at 6 and 7 dpi compared to the isotype control ( Figure 7E ). Whereas the lungs of isotype control mAb-treated animals had infectious virus levels of ~10 6 PFU/g of tissue, we barely detected infectious virus in animals treated with the mAbs 40, 88, 159, 384, or 253H55L ( Figure 7F) . Lung viral RNA levels at 7 dpi also were reduced in animals treated with mAbs 40, 159, 384, and 253H55L, although statistical significance was not achieved with mAb 88 despite mean reductions of ~100-fold ( Figure   7G ). At sites of disseminated infection, notably the heart, spleen, and brain, all anti-SARS-CoV-2 mAbs showed protective activity although mAbs 384 and 253H55L conferred the greatest reductions in viral RNA levels ( Figure 7H-K) . In nasal washes, mAbs 159 and 384

showed the best ability to reduce viral RNA levels ( Figure 7J ). Collectively, these data demonstrate several mAbs in our panel can reduce infection in the upper airway, lower airway, and at distant sites when administered after infection.

There is now a substantial database of antibody/antigen complexes for the SARS-CoV-2 spike (84 PDB depositions as of 12 December 2020, including nanobody structures). The number of unique structures is smaller than this and the focus on potently neutralising public V-regions means that many have near identical binding modes ( Figure S4 ). Here we report, in contrast, a comprehensive analysis of anti-SARS-CoV-2 human mAbs. We measured the neutralisation ability of a set of 377 mAbs from a substantial cohort of COVID-19 patients and identified that 80 of these bind the RBD. For these, we have determined the binding sites of all 80 of these, using a combination of structural methods and a novel computational algorithm based on bio-layer interferometry competition measurements. This defines five binding clusters or epitopes. By analogy with a human torso four of these clusters form a J o u r n a l P r e -p r o o f continuous swathe running from the left shoulder to the neck, right shoulder and down the right flank of the torso whilst the fifth forms a more discrete site towards the left flank. These sites are widely distributed over the surface, however all but one of the 20 most potent (IC 50 <0.1µg/ml) neutralizing mAbs block receptor attachment to the neck. The single exception, mAb 159, binds the NTD and the mechanism of neutralisation is unclear.

The large body of structural results allowed us to dissect the high-resolution details of binding of the major classes of potent neutralisers that bind the RBD. Highly potent ACE2

blocking mAbs map to two sites in the region of the neck and left shoulder, residues E484-F486 bridge the epitopes and are accessible to Fabs binding from a variety of different angles of attack. It is notable that mutation F486L has been identified as a recurrent mutation associated with host-adaptation in mink (van Dorp et al., 2020) and likewise mutation E484K

is found in the recently identified B.1.351 and P.1 lineages. We would expect these changes to impact on the binding of many of our most potent mAbs, including 384. A characterisation of the polyclonal antibody response would give insight into the potential for vaccine escape.

There is a close association between potent neutralizers and public V-genes suggesting that vaccination responses should be strong (Yuan et al., 2020b) . Three public V-region genes are Despite the most potently neutralizing mAbs being close to germline, somatic mutations introduce N-linked glycosylation sites into the variable region of 17.5% of the potent neutralisers. These can contribute to the interaction with the RBD, and although they appear to have relatively little effect on affinity they significantly enhance neutralisation. The enhanced neutralisation we observe (along with other favourable properties, e.g. solubility, stability and mitigation of auto-antigen responses) warrant investigation of production methods to allow variable region glycosylated Fabs to routinely meet regulatory standards .

We find that there is a correlation between Fab vs IgG binding/neutralisation and the mode of attachment to the prefusion spike as seen by cryoEM. Those antibodies which bind the spike in the down conformation appear to show a marked avidity boost to binding and neutralisation when Fab and full length IgG1 are compared (e.g. 316 and 384), suggesting that there is a relationship between the mode of attachment and neutralisation which is still not fully understood, as also seen from the potent neutralisation reported for antibodies that bind at the left and right flank (S309 and EY6A/H014 Lv et al., 2020) epitopes that do not report strong neutralisation in the assay we use in this report.

Finally, we demonstrate that the most potent antibodies we have identified can protect in an animal model, when administered prophylactically or therapeutically. The competition mapping method we have devised suggests a series of combinations of neutralising J o u r n a l P r e -p r o o f antibodies with non-overlapping epitopes which could create an immunotherapy with greater protection and resistance against mutation than a single monoclonal antibody.

The mechanisms of neutralization by antibodies which bind to the NTD is not yet established and will be the subject of further study. 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, David I Stuart (dave@strubi.ox.ac.uk).

Recombinant proteins and antibodies generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

The coordinates and structure factors of the crystallographic complexes are available from the PDB with accession codes 7BEL, 7BEI, 7BEJ, 7BEK, 7BEN, 7BEO, 7BEM, 7BEH, 7BEP (see Table S5 ) Table S5 ). The data that support the findings of this study are available from the corresponding authors on request. Code for the competition driven mAb mapping and clustering (mabscape) is available from https://github.com/helenginn/mabscape https://snapcraft.io/mabscape . 

To construct the expression plasmids for SARS-CoV-2 spike protein, a gene encoding residues 1−1208 of the spike ectodomain with a mutation at the furin cleavage site (residues 682-685) from RRAR to GSAS, proline substitutions at residues 986 and 987, followed by the T4 fibritin trimerization domain, a HRV3C protease cleavage site, a twin Strep Tag and J o u r n a l P r e -p r o o f an 8XHisTag, was synthesized and optimized for mammalian expression (Wrapp et al., 2020 ). An optimized coding sequence was cloned into the mammalian expression vector pHLsec.

Trimeric spike of Expression plasmids were constructed using synthetic fragments coding for human codon- Costar) and kept at −80 °C until use.

The native SARS-CoV-2 nucleoprotein gene was cloned into a pET28a(+) vector ( 

Constructs are as described in Huo et al. 2020 (Huo et al., 2020 and production was as described in . Genes encoding Ig VH, Ig Vκ and Vλ from positive wells were recovered using RT-PCR (210210; QIAGEN). Nested PCR (203205; Qiagen) was then performed to amplify genes encoding γ-chain, λ-chain and κ-chain with 'cocktails' of primers specific for human IgG.

PCR products of genes encoding heavy and light chains were joined with the expression vector for human IgG1 or immunoglobulin κ-chain or λ-chain (gifts from H. Wardemann) by

Gibson assembly. For the expression of antibodies, plasmids encoding heavy and light chains were co-transfected into the 293T cell line by the polyethylenimine method (408727; Sigma), and antibody-containing supernatants were harvested for further characterization.

Heavy chain expression plasmids of specific antibodies were used as templates to amplify the first fragment, heavy chain vector include the variable region and CH1 until Kabat amino acid number 233. The second fragment of thrombin cleavage site and twin-Strep-tag with overlapping ends to the first fragment were amplified. The two fragments were ligated by Gibson assembly to make the Fab heavy chain expression plasmid.

Heavy chain and light chain expression plasmids of specific antibodies were used as a template to amplify variable region gene of heavy and light chain respectively. Firstly, heavy chain gene products having the AgeI-SalII restriction enzyme sites were cloned into a scFv vector which is a modified human IgG expression vector which has a linker between the H chain and L chain genes followed by a thrombin cleavage site and twin-Strep-tags. Light J o u r n a l P r e -p r o o f chain gene products having NheI-NotI restriction enzyme site were cloned into scFv vector containing the heavy chain gene insert to produce scFv expression plasmids.

Protein production was done in HEK293T spike S1 and SARS-CoV-2 spike S2. The plasma endpoint titres (EPTs) were defined as reciprocal plasma dilutions that corresponded to two times the average OD values obtained with mock. EC50 of mAbs were evaluated using non-linear regression (curve-fit), GraphPad

Prism 8 software.

To determine the binding affinity of antibody to SARS-CoV-2 virus, virus was captured onto plates coated with mouse anti-SARS-CoV-2 spike (mAb31 with murine Fc) and then incubated with serial dilutions of SARS-CoV-2-specific human mAbs (full length IgG or Fab) followed by ALP-conjugated anti-human IgG (A8542, Sigma 

The neutralization potential of Ab was measured using a Focus Reduction Neutralization Test (FRNT), where the reduction in the number of the infected foci is compared to a no antibody negative control well. Briefly, serially diluted Ab was mixed with authentic SARS-CoV-J o u r n a l P r e -p r o o f 2/human/AUS/VIC01/2020 (Caly et al., 2020) and incubated for 1 hr at 37 °C. The mixtures were then transferred to Vero cell monolayers and incubated for 2 hrs followed by the addition of 1.5% semi-solid carboxymethyl cellulose (CMC) overlay medium to each well to limit virus diffusion. A focus forming assay was then performed by staining Vero cells with human anti-NP mAb (mAb206) followed by peroxidase-conjugated goat anti-human IgG (A0170; Sigma). Finally, the foci (infected cells) were visualized by adding TrueBlue Peroxidase Substrate. The percentage of focus reduction was calculated and IC 50 was determined using the probit program from the SPSS package.

MAbs 

For the ACE2 competition ELISA, 250 ng of ACE2 protein was immobilized to a MAXIXORP immunoplate and the plates were blocked with 2% BSA in PBS. In the meantime, serially diluted Ab was mixed with recombinant RBD-mFc (40592-V05H; Sino Biological) and incubated for 1 h at 37 °C. The mixtures were then transferred to the ACE2 coated plates and incubated for 1 h followed by goat anti-mouse IgG Fc-AP (Invitrogen #A16093) at 1:2000 dilution. The reaction was developed by the addition of PNPP substrate and stopped with NaOH. The absorbance was measured at 405 nm. The ACE2/RBD binding inhibition rate was calculated by comparing to antibody-free control well. IC 50 were determined using the probit program from the SPSS package.

The stable cell line generation vector pNeoSec was used for cloning of the SARS-Cov2 Spike ectodomain comprising amino acids 27-1208 with mutations of the furin cleavage site (RRAR > GSAS at residues 682-685) and the PP (KV>PP at residues 986-987). At the Nterminus, there is a twin StrepII tag and at the C-terminus fused with a T4 fibritin trimerisation domain, an HRV 3C cleavage site and a His-8 tag. The human embryonic kidney (HEK) Expi293F cells (Thermo Fisher Scientific) were transfected with the construct together with a phiC31 integrase expression plasmid as described earlier (Zhao et al., 2014) .

The polyclonal G418 resistant (1 mg/ml) cell population were used for protein production.

Expi293F cells were grown in adhesion in roller bottles with the high glucose DMEM RBD was concentrated using a 10-kDa ultra centrifugal filter (Amicon) to 10.6 mg ml −1 and stored at -80 °C.

Fab fragments were digested from purified IgGs with papain using a Pierce Fab Preparation Kit (Thermo Fisher), following the manufacturer's protocol.

J o u r n a l P r e -p r o o f

Thermal stability was assessed using Thermofluor (DSF). Briefly, 3 µg of the Ab preparation was used in a 50 µl reaction containing 10 mM HEPES pH 7.5, 100 mM NaCl, 3X

SYPROorange (Thermo Fisher). Samples were heated from 25-97 °C in a RT-PCR machine (Agilent MX3005p) and the fluorescence monitored at 25 °C after every 1 °C of heating.

Melting temperatures (Tm) were calculated by fitting of a 5-parameter sigmoid curve using the JTSA software (P. Bond, https://paulsbond.co.uk/jtsa). Polydispersity was assessed by DLS using 10 µg of the Ab preparation in an UNCLE instrument (Unchained Labs). Freeze thaw experiments on 4 of the mAbs were performed with material at 1 mg/ml by flashfreezing using LN2, thawing and centrifuging an aliquot (10 minutes at 20000 g) before measuring the absorbance at 280nm of the soluble fraction.

Purified RBD was combined separately with Strep-tagged Fab150, Fab58, scFv269 and Fab316 in a 1:1 molar ratio, with final concentrations of 13.2, 9.4, 12.7 and 13.0 mg ml -1 , separately. RBD was combined with Fab45 and Strep-tagged Fab88, Fab75 and Fab253, and

Fab 75 and Strep-tagged chimeric Fab 253H55L in a 1:1:1 molar ratio all with a final concentration of 7 mg ml −1 , separately. Glycosylated RBD was combined with Fab S309 and Fab384 in a 1:1:1 molar ratio with a final concentration of 8 mg ml −1 . These complexes were separately incubated at room temperature for 30 min.

Initial screening of crystals was set up in Crystalquick 96-well X plates (Greiner Bio-One) with a Cartesian Robot using the nanoliter sitting-drop vapor-diffusion method, with 100 nl of protein plus 100 nl of reservoir in each drop, as previously described (Walter et al., 2003) . 

Crystals were soaked in a solution containing 25% glycerol and 75% reservoir solution for a few seconds and then mounted in loops and frozen in liquid nitrogen prior to data collection.

Diffraction data were collected at 100 K at beamline I03 of Diamond Light Source, UK.

Diffraction images of 0.1° rotation were recorded on an Eiger2 XE 16M detector with J o u r n a l P r e -p r o o f exposure time ranging from 0.004 to 0.01 s per frame, beam size 80×20 µm and 100% beam transmission. Data were indexed, integrated and scaled with the automated data processing program Xia2-dials or Xia2-3dii (Winter, 2010; Winter et al., 2018) . For RBD-158 crystal form 2, RBD-316 and the ternary complexes of RBD88-45, RBD-253H55L and RBD-384-S309 data sets of 360° were collected from a single frozen crystal each, and 720° of data from 2 crystals for RBD-150, RBD-scFv269, RBD-158 crystal form 1 and RBD-253-75. Data collection and structure refinement statistics are given in Table S5 .

For all Fab or IgG-Spike complexes, a 3 µL aliquot of S ~0.6 µm (determined by OD) with Fab (1:6 molar ratio) was prepared, aspirated and almost immediately applied to a freshly glow-discharged Cu support Cflat 2/1-200 mesh holey carbon-coated grid (high intensity, 20 s, Plasma Cleaner PDC-002-CE, Harrick Plasma). Excess liquid was removed by blotting for 5-5.5 s with a force of -1 using vitrobot filter paper (grade 595, Ted Pella Inc.) at 4.5 °C, J o u r n a l P r e -p r o o f 100% reported humidity before plunge freezing into liquid ethane using a Vitrobot Mark IV (Thermo Fisher).

40, 253H55L and 253H165L spike complexes:

For sample-specific details, refer to Table S6 .

Movies were collected in compressed tiff format on a Titan Krios G2 (Thermo Fisher) operating at 300 kV with a K3 detector (Gatan) in super resolution counting mode using a custom version of EPU 2.5 (Thermo Fisher). A defocus range of 0.8-2.6 µm was applied with a nominal magnification of x105,000, corresponding to a calibrated pixel size of 0.83 Å/pixel and with a total dose of 43-47 e/ Å 2 , see Table S6 .

Two-times binned movies were then motion corrected and aligned on the fly using Relion(3.1) scheduler (Zivanov et al., 2018 ) with a 5 x 5 patch based alignment. CTFestimation of full-frame non-weighted micrographs was performed with the GCTF (1.06) (Zhang, 2016) module in cryoSPARC(v2.14.1-live) (Punjani et al., 2017) . Poor-quality images were discarded after manual inspection of CTF and motion estimations.

Particles were then blob picked in cryoSPARC (Punjani et al., 2017) and initially extracted with four times binning. After inspection of 2D classes, classes of interest were selected to generate templates for complete particle picking. Binned particles were then subjected to one to three rounds of reference free 2D classification followed by 3D classification with an abinitio derived model before further refinement and unbinning.

For both 150 and 158, two data separate data collections were set up on the same grid, and refined particle sets from each collection were separated by exposure groups before being combined. For 150, a total of 77,265 exposure-group split particles were initially combined (51,554 from 4726 movies and 25,711 from 2079 movies), re-classified into five classes, and the two best classes (42,655 particles) subjected to further non-uniform refinement, with obvious density for Fab bound to one RBD in an 'up' conformation. Notably, discarded classes included a high proportion of undecorated S (28,463 particles, 4.4 Å reported resolution at GSFSC = 0.143, -43 Å 2 B-factor).

Classification using heterogeneous refinement in cryoSPARC was found to be generally poor, and, instead, 3D variability analysis was employed to try to better resolve full spike-Fab structures. Local refinements were also performed with masks focused around the Fab/RBD region (not reported here), but maps were still insufficient to clearly build a model at the J o u r n a l P r e -p r o o f RBD/Fab interface and far inferior to the crystallographic maps. 3D variability analysis was found to be essential for isolating the RBD up and RBD down conformations for 159-IgG.

Results from this are presented for 159-IgG and 384. Briefly, data were separated into eight clusters using the 3D variability analysis module with a 6 Å resolution filter and a mask around the RBD/Fab region. Masks were generated by initially rigid body fitting a model of the spike and a Fab into a refined map in Chimera before selecting an area of the model including the RBD and fab and using the 'color zone' module to crop out this desired part of the map. The resulting map was smoothed with a gaussian filter (Pettersen Ef Fau -Goddard et al., 2004) , converted into a mask format using Relion3.1 'Mask Create' before import into cryoSPARC. Resolution estimates quoted in the Table S6 were taken from Gold standard-FSC (FSC = 0.143) reported in the local resolution module in cryoSPARC (Punjani et al., 2017) .

Competition assay of anti-RBD antibodies was performed on a Fortebio Octet RED96e machine with Fortebio Anti-HIS (HIS2) Biosensors. 2 µg ml −1 of His-tagged RBD dissolved in the running buffer (10 mM HEPES, pH 7.4 and 150 mM NaCl) was used as the ligand and was first immobilized onto the biosensors. The biosensors were then washed in the running buffer to remove unbound RBD. Each biosensor was dipped into different saturating antibodies (Ab1) to saturate the bound RBD, except one biosensor was into the running buffer in this step, acting as the reference. The concentration of saturating antibodies used was 15 µg ml −1 . Higher concentrations were applied if 15 µg ml −1 was not enough to obtain saturating. Then all biosensors were washed with the running buffer again and dipped into wells containing the same competing antibody (Ab2). The concentration of competing antibodies used was 5 µg ml −1 . The Y-axis values of signals of different saturating antibodies J o u r n a l P r e -p r o o f in this step were divided by the value of the reference channel to get ratio results of different Ab1-Ab2 pairs. Ratio result close to 0 indicated total competition while 1 indicated no competition. In total, 50 IgGs and 4 Fabs (Fabs 40, EY6A , FD5D

(unpublished) and S309 ) were used as the saturating antibodies and 80

IgGs as the competing antibodies.

Gross binning of antibodies: Competition values were prepared for cluster analysis and binning by capping all competition values between 0 and 1. Competition values between antibodies i and j were averaged with the competition value for j and i when both were available. Cluster4x (Ginn, 2020) was used to cluster antibodies into three distinct groups using single value decomposition on the matrix of competition values. where r is the working radius of the antibody, set to 11 Å, accounting for the approximate antibody radius. The distance between the pair of antibodies at a given evaluation of the function is given by d in Angstroms. The target function was the sum of squared differences between the competition estimation and the competition value from SPR data.

Obtaining a self-consistent set of refined antibody positions: Minimisation was carried out globally by 1000 macrocycles of Monte Carlo-esque sampling using LBFGS refinement. A random starting position for each antibody was generated by randomly assigning a starting vertex on the RBD mesh and the target function minimised for 20 cycles considering data points for pairs with at least one fixed antibody, followed by 40 cycles for all data points.

Between each cycle, antibody positions were locked onto the nearest mesh vertex.

Depending on the starting positions of antibodies, results were a mixture of well-refined and poorly refined solutions. Results were ordered in ascending target function scores. Positions of antibodies for each result was passed into cluster4x as dummy C-alpha positions (Ginn, 2020) . A clear self-consistent solution was enriched in lower target function scores and separated using cluster4x for further analysis. The average position for each antibody was chosen as the sampled position which had the lowest average square distance to very other sampled position, and the RMSD calculated from all contributing antibody positions.

Tissues were weighed and homogenized with zirconia beads in a MagNA Lyser instrument (Roche Life Science) in 1000 µL of DMEM supplemented to contain 2% heat-inactivated FBS. Tissue homogenates were clarified by centrifugation at 10,000 rpm for 5 min and stored at −80 °C. RNA was extracted using the MagMax mirVana Total RNA isolation kit (Thermo Scientific) on a Kingfisher Flex extraction robot (Thermo Scientific). RNA was reverse transcribed and amplified using the TaqMan RNA-to-CT 1-Step Kit (ThermoFisher). Reverse transcription was carried out at 48 °C for 15 min followed by 2 min at 95 °C. Amplification was accomplished over 50 cycles as follows: 95 °C for 15 s and 60 °C for 1 min. Copies of SARS-CoV-2 N gene RNA in samples were determined using a previously published assay (PubMed ID 32553273). Briefly, a TaqMan assay was designed to target a highly conserved region of the N gene (Forward primer: ATGCTGCAATCGTGCTACAA; Reverse primer:

Probe: /56-FAM/TCAAGGAAC/ZEN/AACATTGCCAA/3IABkFQ/). This region was included in an RNA standard to allow for copy number determination. The reaction mixture contained final concentrations of primers and probe of 500 and 100 nM, respectively.

Vero-furin cells (Mukherjee et al., 2016) were seeded at a density of 2.5×10 5 cells per well in flat-bottom 12-well tissue culture plates. The following day, medium was removed and replaced with 200 µL of 10-fold serial dilutions of the material to be titrated, diluted in DMEM+2% FBS. After incubation for 1 h at 37 o C, 1 mL of methylcellulose overlay was J o u r n a l P r e -p r o o f

Plates were incubated for 72 h, then fixed with 4% paraformaldehyde (final concentration) in phosphate-buffered saline for 20 min. Plates were stained with 0.05% (w/v) crystal violet in 20% methanol and washed twice with distilled

Affinity determination using biolayer interferometry

ForteBio) was used to determine the binding affinities of antibodies with RBD or spike. Anti-RBD IgGs were immobilized onto AR2G biosensors (ForteBio) while RBD was used as the analyte with serial dilutions. For IgG159, spike was immobilised onto

ELISA K d and EC50 values were estimated using nonlinear regression curve-fitting analyses of binding data

BLI Kd values were calculated using Data Analysis HT 11.1 (ForteBio) with a 1:1 global fitting model. Statistical analysis of weight change and viral burden in vivo were determined by two-way ANOVA with Sidak's post-test and Kruskal-Wallis test with Dunn's post-test

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Glycosylation in Immunity The Emerging Importance of IgG Fab Rispens and Yoann Rombouts

Distinct conformational states of SARS-CoV-2 spike protein

Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia

The SARS-CoV-2 Spike harbours a lipid binding pocket which modulates stability of the prefusion trimer

RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak

Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2

COVID-19 antibodies on trial

Genetic and structural basis for recognition of SARS-CoV-2 spike protein by 2 a two-antibody cocktail 3 4

Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy

Coot: Model-building tools for molecular graphics

Pre-clustering data sets using cluster 4 x improves the signal-to-noise ratio of high-throughput crystallography drug-screening analysis

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Plasmablast-derived antibody response to acute SARS-CoV-2 infection in humans

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation

Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

SARS-CoV-2 vaccines in development

Antibody Protects from Lung Pathology in a COVID-19 Hamster Model

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies

Macromolecular structure determination using X-rays, neutrons and electrons: Recent developments in Phenix

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Automated electron microscope tomography using robust prediction of specimen movements

Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors

Lethal Infection of K18-hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus

Enhancing dengue virus maturation using a stable furin over-expressing cell line

UCSF Chimera--a visualization system for exploratory research and analysis

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Algorithms for rapid unsupervised cryo-EM structure determination

Dynamic Asymmetry Exposes 2019-nCoV Prefusion Spike

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Characterization of severe acute respiratory syndrome-associated coronavirus

spike glycoprotein-mediated viral entry

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Recurrent mutations in SARS-CoV-2 genomes isolated from mink point to rapid host-adaptation

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

A procedure for setting up high-throughput nanolitre crystallization experiments. I. Protocol design and validation

A plate-based high-throughput assay for virus stability and vaccine formulation

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

Xia2: An expert system for macromolecular crystallography data reduction

DIALS : implementation and evaluation of a new integration package

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Antibody variable region glycosylation: Position effects on antigen binding and carbohydrate structure

Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein

An Alternative Binding Mode

Antibodies to the SARS-CoV-2 Receptor Binding Domain

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

A thermostable, closed SARS-CoV-2 spike protein trimer

Off-rate screening for selection of high-affinity anti-drug antibodies

A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV

Structural basis of a shared antibody response to SARS-CoV-2

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains

Gctf: Real-time CTF determination and correction

Challenges of glycosylation analysis and control: An integrated approach to producing optimal and consistent therapeutic drugs

A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV

Lysosome sorting of βglucocerebrosidase by LIMP-2 is targeted by the mannose 6-phosphate receptor

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

New tools for automated high-resolution cryo-EM structure determination in RELION-3. Elife

Potently neutralizing and protective human J o u r n a l P r e -p r o o f antibodies against SARS-CoV-2